The term “high-grade non-Hodgkin’s lymphomas” refers to three histologic subtypes categorized in the Working Formulation1 classification (Table 10–1). At that time, the definitions of low-, intermediate-, and high-grade lymphomas were based on differences in survival, and those with the worst prognoses were considered the high-grade histologic subtypes of small noncleaved cell lymphoma (SNCCL),...

BACKGROUND/AIMS Endoscopic ultrasound (EUS) plays a crucial role in the assessment and treatment of low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma; however, interobserver variation, inadequate accuracy in judging the depth of tumor invasion, and histological heterogeneity of the tumor can limit its role. Thus, we have assessed the role of (18)F-FDG PET scans in the manageme...

Objective: Angiogenesis is critical for the development of tumors. Although vascular endothelial growth factor is a well-known proangiogenic factor, its impact on B-cell non-Hodgkin’s lymphoma is not clear. The aim of this study is to evaluate vascular endothelial growth factor expression in subtypes of B-cell non-Hodgkin’s lymphoma . Material and Method: Fifty-one patients with diagnoses of lo...

BACKGROUND A relatively high incidence of pathological conditions in retrieved femoral heads, including a group of patients having low grade B-cell lymphoma, has been described before. At short term follow up none of these patients with low-grade B-cell lymphoma showed evidence of systemic disease. However, the long term follow up of these patients is not known. METHODS From November 1994 up ...

In the January 2002 issue of Annals of Oncology, Bertz et al. showed nicely that allogeneic stem cell transplantation (SCT) using reduced-intensity conditioning (RIC) is an effective treatment for resistant low/intermediate-grade lymphoma [1]. They further concluded that allogeneic SCT might be a promising treatment option for non-Hodgkin’s lymphoma in general, and that RIC can be expected to b...

BACKGROUND The purpose of this study was to assess the efficacy and safety of ISIS 3521, an antisense phosphorothioate oligonucleotide to protein kinase C alpha in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Twenty-six patients received ISIS 3521 (2 mg/kg/day) as a continuous infusion over 21 days of each 28-day cycle. RESULTS The median age of the pa...

BACKGROUND The occurrence of B cell non-Hodgkin's lymphoma is a complication of Sjögren's syndrome (SS) and, at least in some countries, of chronic hepatitis C virus (HCV) infection. Lymphomas occurring in both diseases share a number of characteristics: predominance of low grade, marginal zone histological type, frequency of mucosal localisation, possible transformation into a large B cell lym...

Non-Hodgkin lymphoma usually arises from lymphoid or nodal tissue, and can occasionally involve other sites. Extra-nodal marginal-zone B-cell lymphoma of mucosaassociated lymphoid tissue (MALT lymphoma) is uncommon and constitutes around 8% of all non-Hodgkin lymphomas. Most MALT lymphomas are of gastric origin and lung involvement is rare. Primary pulmonary lymphoma is defined as clonal lympho...

PURPOSE Immunotherapy using monoclonal antibodies to specifically target B cells has provided new hope to many patients with indolent lymphomas, particularly those with chemotherapy-refractory disease. Lymphomas are extremely sensitive to radiation, and significant progress has been made over the last decade in the development of radioimmunotherapy with anti-CD20 antibodies. MATERIALS AND MET...